scholarly journals Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA

Cancer ◽  
2016 ◽  
Vol 122 (19) ◽  
pp. 3015-3023 ◽  
Author(s):  
Masanori Hayashi ◽  
David Chu ◽  
Christian F. Meyer ◽  
Nicolas J. Llosa ◽  
Gregory McCarty ◽  
...  
Keyword(s):  
Ewing Sarcoma ◽  
Disease Burden ◽  
Tumor Dna ◽  
Plasma Tumor Dna

Circulating plasma tumor DNA is superior to plasma tumor RNA detection in Ewing sarcoma patients

2021 ◽  
Author(s):  
Avery Bodlak ◽  
Kyle Chang ◽  
Jessica Channel ◽  
Amy Treece ◽  
Nathan Donaldson ◽  
...  
Keyword(s):  
Ewing Sarcoma ◽  
Rna Detection ◽  
Tumor Dna ◽  
Plasma Tumor Dna

scholarly journals Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease

2019 ◽  
pp. 1-11 ◽  
Author(s):  
Matthew L. Hemming ◽  
Kelly Klega ◽  
Justin Rhoades ◽  
Gavin Ha ◽  
Kate E. Acker ◽  
...  
Keyword(s):  
Disease Progression ◽  
Tumor Size ◽  
Disease Burden ◽  
Progressive Disease ◽  
Circulating Tumor Dna ◽  
Tumor Burden ◽  
Blood Draw ◽  
Cell Free Dna ◽  
Free Dna ◽  
Tumor Dna

Purpose Leiomyosarcoma (LMS) is a soft-tissue sarcoma characterized by multiple copy number alterations (CNAs) and without common recurrent single-nucleotide variants. We evaluated the feasibility of detecting circulating tumor DNA (ctDNA) with next-generation sequencing in a cohort of patients with LMS whose tumor burden ranged from no evidence of disease to metastatic progressive disease. Patients and Methods We evaluated cell-free DNA in plasma samples and paired genomic DNA from resected tumors from patients with LMS by ultra-low passage whole-genome sequencing. Sequencing reads were aligned to the human genome and CNAs that were identified in cell-free DNA and tumor DNA by ichorCNA software to determine the presence of ctDNA. Clinical data were reviewed to assess disease burden and clinicopathologic features. Results We identified LMS ctDNA in 11 (69%) of 16 patients with disease progression and total tumor burden greater than 5 cm. Sixteen patients with stable disease or low disease burden at the time of blood draw were found to have no detectable ctDNA. Higher ctDNA fraction of total cell-free DNA was associated with increasing tumor size and disease progression. Conserved CNAs were found between primary tumors and ctDNA in each case, and recurrent CNAs were found across LMS samples. ctDNA levels declined after resection of progressive disease in one case and became detectable upon disease relapse in another individual patient. Conclusion These results suggest that ctDNA, assayed by a widely available sequencing approach, may be useful as a biomarker for a subset of patients with uterine and extrauterine LMS. Higher levels of ctDNA correlate with tumor size and disease progression. Liquid biopsies may assist in guiding treatment decisions, monitoring response to systemic therapy, surveying for disease recurrence, and differentiating benign and malignant smooth muscle tumors.

Abstract SY11-01: Plasma tumor DNA: Changing the paradigm for administering systemic therapies.

2013 ◽  
Author(s):  
Julia A. Beaver ◽  
Patricia Valda ◽  
Danijela Jelovac ◽  
Michaela J. Higgins ◽  
Ben H. Park
Keyword(s):  
Tumor Dna ◽  
Plasma Tumor Dna ◽  
Systemic Therapies

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8539-8539
Author(s):  
Florian Scherer ◽  
David Matthew Kurtz ◽  
Michael Richard Green ◽  
Aaron M. Newman ◽  
Daniel M. Klass ◽  
...  
Keyword(s):  
B Cell ◽  
Disease Burden ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Circulating Tumor Dna ◽  
Large B Cell Lymphoma ◽  
Pre Treatment ◽  
Tumor Dna ◽  
Large B Cell

scholarly journals Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA

2015 ◽  
Vol 48 (15) ◽  
pp. 993-998 ◽  
Author(s):  
Patricia Valda Toro ◽  
Bracha Erlanger ◽  
Julia A. Beaver ◽  
Rory L. Cochran ◽  
Dustin A. VanDenBerg ◽  
...  
Keyword(s):  
Blood Collection ◽  
Blood Collection Tubes ◽  
Tumor Dna ◽  
Plasma Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document